KALA BIO Secures $10.75 Million in Significant Funding
KALA BIO, Inc. (NASDAQ: KALA), a pioneering biopharmaceutical company focused on advancing innovative therapies for rare eye diseases, has successfully entered into a securities purchase agreement with a select group of accredited institutional investors. This agreement involves the sale of shares of its common stock and Series I Convertible Non-Redeemable Preferred Stock, totaling approximately $10.75 million in gross proceeds.
Details of the Private Placement
This private placement has attracted both new and existing investors, showcasing confidence in KALA's mission. Notable participants in this funding round include SR One, Cormorant Asset Management, Woodline Partners, and other specialized life sciences investors.
Share Distribution and Financial Provisions
KALA BIO plans to sell 1,340,603 shares of common stock priced at $6.44 each, alongside 3,286 shares of Series I Preferred Stock set at $644.00 each. The anticipated closing date for this private placement is just around the corner, pending customary closing conditions.
Utilizing Funds for Growth
With the combination of its current cash resources and the expected influx from the private placement, KALA is optimistic about funding its operations well into early 2026. The company is strategically directing these funds towards advancing the clinical development of KPI-012, a treatment aimed at addressing persistent corneal epithelial defects. Additionally, funds will support general corporate purposes.
Advancements in Clinical Trials
KALA is making strides in recruiting participants for its ongoing Phase 2b CHASE trial of KPI-012, with over 40 clinical trial sites currently open and enrolling. In remarks by Mark Iwicki, Chair and CEO of KALA BIO, the management expressed gratitude for the support from both new and current shareholders, emphasizing the importance of this financing at a pivotal juncture for the company. With over 80% enrollment completion in the CHASE trial, KALA aims to share topline data in the upcoming quarters of 2025. The outcomes from this trial hold the potential to lay the groundwork for essential trials needed for the submission of a Biologics License Application (BLA) to the FDA.
Regulatory Considerations
The securities being sold through this private placement are not registered under the Securities Act of 1933, nor are they compliant with state securities laws. This stipulation mandates that these securities can only be offered or sold in the United States if they adhere to a valid registration statement or meet an applicable exemption. KALA has committed to filing a registration statement with the U.S. SEC to facilitate the resale of the common stock issued, as well as shares that may be obtained upon conversion of the Series I Preferred Stock.
About KALA BIO, Inc.
KALA BIO is dedicated to developing cutting-edge therapies for rare and severe ocular diseases through its proprietary mesenchymal stem cell secretome (MSC-S) platform. Their lead candidate, KPI-012, is composed of a unique blend of human-derived biofactors designed to enhance corneal healing, addressing critical needs within the ocular health landscape. The company also holds Orphan Drug and Fast Track designations from the FDA for KPI-012, emphasizing its commitment to addressing rare diseases such as persistent corneal epithelial defects.
Future Directions
Additionally, KALA has outlined aspirations to explore KPI-012's potential for treating Limbal Stem Cell Deficiency and other ocular diseases. Preclinical evaluations are already underway to investigate its applications for retinal degenerative disorders like Retinitis Pigmentosa and Stargardt Disease.
Frequently Asked Questions
What is the total amount KALA BIO has secured through the placement?
KALA BIO has secured approximately $10.75 million in this private placement.
Who are the main investors involved in this private placement?
Notable investors include SR One, Cormorant Asset Management, Woodline Partners, and other prominent life science investors.
What will the proceeds be used for?
The proceeds will be used for advancing the clinical development of KPI-012 and for general corporate purposes.
What is the timeline for the closing of this private placement?
The private placement is expected to close shortly, around the end of December 2024, pending customary conditions.
What therapeutic area does KPI-012 target?
KPI-012 is intended for the treatment of persistent corneal epithelial defects and potentially for other rare corneal diseases.
